Benjamin Besse

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Benjamin Besse
Jun 29, 2025, 17:43 | Career
Benjamin Besse: Honoured to Have Been Appointed President-Elect of the EORTC
Benjamin Besse, President-Elect of EORTC and Head of Clinical Research at Gustave Roussy, shared a…
Jun 29, 2025, 17:17 | Blog
EORTC Announces Benjamin Besse as President-Elect and New Co-Chairs of Scientific Chairs Council
EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn: "We’re…
Apr 28, 2025, 05:34 | Science
Benjamin Besse discussed de-escalation strategies in patient management and clinical trials at ELCC25
Praveen Kumar Marimuthu, Medical Oncologist at CMC Vellore, shared a post on LinkedIn: "Benjamin Besse…
Apr 14, 2025, 07:18 | Insight
Roberto Ferrara: Time to tailor chemo-IO in early stage NSCLC
Roberto Ferrara, Medical Oncologist,Researcher in Thoracic Oncology and Molecular Immunology at Vita-Salute San Raffaele University,…
Apr 2, 2025, 13:48 | Blog
David Planchard: Lung preceptorship leading by Fabrice Barlesi at Gustave Roussy
David Planchard, Thoracic Pathologist Committee at Gustave Roussy, shared a post on X: "More teaching/exchanges during this…
Mar 31, 2025, 11:21 | Blog
Courageous keynote lecture from Benjamin Besse
Rodrigo Lastra del Prado, Medical Oncologist of Thoracic Tumor Unit at University Hospital, Zaragoza, Spain,…
Mar 29, 2025, 18:03 | Blog
Marina Puchinskaya: It was an incredible lecture from ELCC 25
Marina Puchinskaya, Oncologist at "Kravira" Medical Centre, shared ESMO's post on LinkedIn: "It was an…
Mar 29, 2025, 17:02 | Blog
Julien Mazieres: Great talk by ⁦Benjamin Besse⁩ on de-escalation strategies in oncology at ELCC25
Julien Mazieres, Head of Thoracic Diseases Department at the University Hospital Center of Toulouse, shared…
Mar 27, 2025, 15:53 | Blog
Highlights from ELCC Day 1
The European Lung Cancer Congress (ELCC 2025) takes place in Paris from March 26-29, 2025,…
Mar 26, 2025, 16:35 | Drugs
MARIPOSA trial results presented at ELCC25 - BREAKING from Paris
MARIPOSA reports OS benefit with amivantamab–lazertinib vs osimertinib monotherapy! This year, the European Lung Cancer…
Mar 19, 2025, 05:01 | Blog
Roberto Borea: Utilizing ctDNA in mechanisms of resistance to targeted therapies in patients with metastatic NSCLC
Roberto Borea, PhD student at The University of Genoa, shared a paper Sophie M. Ernst…
Jan 31, 2025, 12:46 | Insight
5 papers about lung cancer by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Jan 27, 2025, 09:42 | Science
Giannis Mountzios: Are we treating our NSCLC patients with the optimal dose and duration of immunotherapy?
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant…
Jan 26, 2025, 12:08 | Science
Jordi Remon: De-Escalation strategies with immune checkpoint blockers in NSCLC
Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared a recent article by him and colleagues…
Jan 25, 2025, 04:12 | Science
Jarushka Naidoo: De-Escalation Strategies With ICIs in NSCLC - Do We Already Have Enough Evidence?
Jarushka Naidoo, Thoracic oncologist at the Beaumont Hospital Dublin, shared a post on X about…
Jan 7, 2025, 13:33 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Jan 3, 2025, 21:19 | Science
Luis Raez: We have a lot of survivors on osimertinib alone that will need second-line therapy in the future
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post…
Jan 3, 2025, 16:25 | Science
Amivantamab Plus Lazertinib in Patients With EGFR-mutant NSCLC by Benjamin Besse et al.
A recent article by Benjamin Besse et al. was mentioned by Akhil Santhosh, Medical Oncology Specialist at…
Dec 27, 2024, 17:00 | Science
Corinne Faivre-Finn: An International EORTC Survey on Stage III NSCLC resectability
Corinne Faivre-Finn, Professor of Thoracic Radiation Oncology at the University of Manchester, posted on X…
Dec 26, 2024, 15:22 | Insight
Ilias Houda: Our EORTC survey on resectability of stage III NSCLC
Ilias Houda, PhD Candidate in Thoracic Oncology at Amsterdam UMC, shared a post on LinkedIn…
Dec 23, 2024, 12:47 | Science
Giuseppe Banna: Selpercatinib for RET fusion+ NSCLC by Benjamin Besse et al.
A recent paper by Benjamin Besse, Director of Clinical Research at the Gustave Roussy Institute,…
Dec 2, 2024, 09:46 | Positive
Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As November came to a close, it's an ideal time to reflect on Lung Cancer…
Nov 25, 2024, 17:53 | Insight
Safety of Lorlatinib in ALK positive NSCLC
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber and Harvard Medical School, shared a recent article…
Nov 24, 2024, 13:36 | Insight
Eric K. Singhi: Is it time to universally prescribe 1L lorlatinib for all?
Eric K. Singhi, Assistant Professor in the Department of General Oncology within the Division of…
Sep 19, 2024, 16:38 | Blog
Benjamin Besse: Impressive benefit for Lenvatinib-Pembrolizumab in patients with thymic carcinoma and B3 thymoma
Estela Rodriguez shared a post by Benjamin Besse, Head of Clinical Research at Gustave Roussy,…
Sep 19, 2024, 09:23 | Insight
Jessica Lin: Preclinical development and proof-of-concept clinical activity of NVL-655
Jessica Lin shared a post on LinkedIn: "We are pleased to share this article out today…
Sep 17, 2024, 15:07 | Blog
Stephen V Liu: Data from ARROS-1 study of NVL-520 in ROS1 NSCLC
Stephen V Liu shared a post on X: ''Benjamin Besse presents data from ARROS-1 study…
Sep 15, 2024, 16:26 | Societies
43 Posts Not To Miss From ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 14, 2024, 15:40 | Insight
Key Findings from the PECATI Trial at ESMO 2024
The results of the PECATI trial were recently presented at ESMO 2024. The PECATI trial…
Sep 7, 2024, 07:32 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 9, 2024, 01:47 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 5, 2024, 01:55 | Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Jul 3, 2024, 17:29 | Blog
Benjamin Besse: Stop pembro after 2 years?
Benjamin Besse, Head of Clinical Research at Gustave Roussy, shared on X: "Stop pembro after…
Jun 28, 2024, 04:59 | Blog
Mihaela Aldea received a 2024 IASLC YIA
Mihaela Aldea, Medical Oncologist at the Gustave Roussy, shared a post on X: "Honored to…
Jun 27, 2024, 14:15 | Blog
David Planchard: Nice post-ASCO24 at Gustave Roussy with the lung session
David Planchard shared on LinkedIn: "Nice post-ASCO24 Gustave Roussy with the lung session. What wonderful…
Jun 10, 2024, 13:02 | Blog
Lung Cancer Europe has two valuable webinars coming up in June and July
Lung Cancer Europe shared on X/Twitter: "Lung Cancer Europe (LuCE) has two valuable webinars coming up…
May 25, 2024, 05:54 | Blog
Patrizia Giannatempo: Thanks, ESMO for the opportunity to discuss the landmark EV-302 paper
Patrizia Giannatempo, Medical Oncologist at IRCCS National Cancer Institute Foundation, shared on X: "Thanks, ESMO…
May 24, 2024, 13:02 | Blog
Jose Carlos Benitez: Thrilled to have organized the EORTC LCG spring meeting at home Ayuntamiento de Málaga
Jose Carlos Benitez, Medical Oncologist at University Hospital Virgen de la Victoria, shared a post on…
May 23, 2024, 14:25 | Insight
Benjamin Besse: Should we infuse IO in the morning?
Benjamin Besse, Head of Clinical Research on Gustave Roussy, shared on X: "Should we infuse…
May 18, 2024, 00:16 | Blog
Luis E. Raez: Analysis of PRO data from the landmark LIBRETTO-001 trial
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post on X: "In this…
May 12, 2024, 13:30 | Blog
Biagio Ricciuti: Insightful discussions at Rome Lung 24
Biagio Ricciuti shared a post by Stephen Liu on X and added: "Had a great…
Apr 18, 2024, 16:36 | Insight
New Paper Alert! Understanding the Effects of Post-irAE Treatments With Immunosuppressant Agents in Cancer Immunotherapy
Understanding the Effects of Post-irAE Treatments With Immunosuppressant Agents in Cancer Immunotherapy Authors: Pierre-Louis Cariou,…
Apr 17, 2024, 10:09 | Positive
Yaniss B.: The 3rd edition of the Transatlantic Exchanges in Oncology was a huge success!
Yaniss B, Valorisation Officer at Gustave Roussy Transfert shared on X: “The 3rd edition of the…
Apr 9, 2024, 09:03 | Insight
Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Mar 21, 2024, 15:19 | Blog
Jarushka Naidoo: Getting ready to plan ASCO24
Jarushka Naidoo shared a post on X/Twitter: “Getting ready to plan ASCO24! And with a…
Sep 12, 2023, 20:05 | Insight
Benjamin Besse: Time to change our practice and give our IOs in the morning?
Benjamin Besse, Head of Clinical Research at Gustave Roussy, shared on Twitter: "Accumulative publications showing…
All: 46 Posts: 1 - 100
Special Coverage